Erythropoietin promoter polymorphism is associated with treatment efficacy and severe hematologic toxicity for platinum-based chemotherapy

References 

• Torre LA, Bray F, Siegel RL, et al. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65(2):87-108.
   Google Scholar
• Rabik C, Dolan M. Molecular mechanisms of resistance and toxicity associated with platinating agents. Cancer Treat Rev. 2007;33(1):9–23.
   PubMed Web of Science ®Google Scholar
• Carey P. Drug-induced myelosuppression: diagnosis and management. Drug Saf. 2003;26(10):691–706.
   PubMed Web of Science ®Google Scholar
• Jiang N, Chen X, Zhao Y. Analysis of the risk factors for myelosuppression after concurrent chemoradiotherapy for patients with advanced non-small cell lung cancer. Support Care Cancer. 2013;21(3):785–791.
   PubMed Web of Science ®Google Scholar
• Jelkmann W. Molecular biology of erythropoietin. Intern Med. 2004;43(8):649–659.
   PubMed Web of Science ®Google Scholar
• Jeong J, Hoxhaj G, Socha A, et al. An erythropoietin autocrine/paracrine axis modulates the growth and survival of human prostate cancer cells. Mol Cancer Res. 2009;7(7):1150–1157. .
   PubMed Web of Science ®Google Scholar
• Merkle R, Steiert B, Salopiata F, et al. Identification of cell type-specific differences in erythropoietin receptor signaling in primary erythroid and lung cancer cells. PLoS Comput Biol. 2016;12(8):e1005049. .
   PubMed Web of Science ®Google Scholar
• Dagnon K, Pacary E, Commo F, et al. Expression of erythropoietin and erythropoietin receptor in non-small cell lung carcinomas. Clin Cancer Res. 2005;11(3):993–999.
   PubMed Web of Science ®Google Scholar
• Mohyeldin A, Lu H, Dalgard C, et al. Erythropoietin signaling promotes invasiveness of human head and neck squamous cell carcinoma. Neoplasia (New York, NY). 2005;7(5):537–543. .
   PubMed Web of Science ®Google Scholar
• Saintigny P, Besse B, Callard P, et al. Erythropoietin and erythropoietin receptor coexpression is associated with poor survival in stage I non-small cell lung cancer. Clin Cancer Res. 2007;13(16):4825–4831. .
   PubMed Web of Science ®Google Scholar
• Rades D, Setter C, Dahl O, et al. Prognostic impact of erythropoietin expression and erythropoietin receptor expression on locoregional control and survival of patients irradiated for stage II/III non-small-cell lung cancer. Int J Radiat Oncol Biol Phys. 2011;80(2):499–505. .
   PubMed Web of Science ®Google Scholar
• Peng B, Kong G, Yang C, et al. Erythropoietin and its derivatives: from tissue protection to immune regulation. Cell Death Dis. 2020;11(2):79. .
   PubMed Web of Science ®Google Scholar
• Rjiba-Touati K, Ayed-Boussema I, Belarbia A, et al. Protective effect of recombinant human erythropoietin against cisplatin cytotoxicity and genotoxicity in cultured Vero cells. Exp Toxicol Pathol. 2013;65:181–187.
   PubMedGoogle Scholar
• Abhold E, Rahimy E, Wang-Rodriguez J, et al. Recombinant human erythropoietin promotes the acquisition of a malignant phenotype in head and neck squamous cell carcinoma cell lines in vitro. BMC Res Notes. 2011;4:553.
   PubMedGoogle Scholar
• Vázquez-Mellado M, Cortés-Ballinas L, Blanco-Flores I, et al. Erythropoietin promotes expression of survivin via STAT3 activation and reduces sensitivity to cisplatin in cervical cancer cells. Oncol Rep. 2019;41(2):1333–1341. .
   PubMed Web of Science ®Google Scholar
• Wright J, Ung Y, Julian J, et al. Randomized, double-blind, placebo-controlled trial of erythropoietin in non-small-cell lung cancer with disease-related anemia. J clin oncol. 2007;25(9):1027–1032. .
   PubMed Web of Science ®Google Scholar
• Henke M, Mattern D, Pepe M, et al. Do erythropoietin receptors on cancer cells explain unexpected clinical findings? J clin oncol. 2006;24(29):4708–4713. .
   PubMed Web of Science ®Google Scholar
• Hedley B, Allan A, Xenocostas A. The role of erythropoietin and erythropoiesis-stimulating agents in tumor progression. Clin Cancer Res. 2011;17(20):6373–6380.
   PubMed Web of Science ®Google Scholar
• Tong Z, Yang Z, Patel S, et al. Promoter polymorphism of the erythropoietin gene in severe diabetic eye and kidney complications. Proc Natl Acad Sci U S A. 2008;105(19):6998–7003. .
   PubMed Web of Science ®Google Scholar
• Therasse P, Arbuck S, Eisenhauer E, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000;92(3):205–216. .
   PubMed Web of Science ®Google Scholar
• Belenkov A, Shenouda G, Rizhevskaya E, et al. Erythropoietin induces cancer cell resistance to ionizing radiation and to cisplatin. Mol Cancer Ther. 2004;3(12):1525–1532.
   PubMed Web of Science ®Google Scholar
• Sun C, Yao Y, Zhang C, et al. EPO attenuates cisplatin-induced ototoxicity in HEI-OC1 auditory cell via the Nrf2-ARE signaling pathway. Otol Neurotol. 2019;40(7):965–971. .
   PubMed Web of Science ®Google Scholar
• Sharawy N, Rashed L, Youakim M. Evaluation of multi-neuroprotective effects of erythropoietin using cisplatin induced peripheral neurotoxicity model. Exp Toxicol Pathol. 2015;67(4):315–322.
   PubMedGoogle Scholar
• Rjiba-Touati K, Boussema I, Belarbia A, et al. Protective effect of recombinant human erythropoietin against cisplatin-induced oxidative stress and nephrotoxicity in rat kidney. Int J Toxicol. 2011;30(5):510–517. .
   PubMed Web of Science ®Google Scholar
• Kong D, Zhuo L, Gao C, et al. Erythropoietin protects against cisplatin-induced nephrotoxicity by attenuating endoplasmic reticulum stress-induced apoptosis. J Nephrol. 2013;26(1):219–227. .
   PubMed Web of Science ®Google Scholar
• Rjiba-Touati K, Ayed-Boussema I, Skhiri H, et al. Induction of DNA fragmentation, chromosome aberrations and micronuclei by cisplatin in rat bone-marrow cells: protective effect of recombinant human erythropoietin. Mutat Res. 2012;747(2):202–206. .
   PubMed Web of Science ®Google Scholar
• Rjiba-Touati K, Ayed-Boussema I, Belarbia A, et al. Recombinant human erythropoietin prevents cisplatin-induced genotoxicity in rat liver and heart tissues via an antioxidant process. Drug Chem Toxicol. 2012;35(2):134–140. .
   PubMed Web of Science ®Google Scholar
• Watanabe D, Suzuma K, Matsui S, et al. Erythropoietin as a retinal angiogenic factor in proliferative diabetic retinopathy. N Engl J Med. 2005;353(8):782–792. .
   PubMed Web of Science ®Google Scholar
• Amanzada A, Goralczyk A, Reinhardt L, et al. Erythropoietin rs1617640 G allele associates with an attenuated rise of serum erythropoietin and a marked decline of hemoglobin in hepatitis C patients undergoing antiviral therapy. BMC Infect Dis. 2014;14:503.
   PubMed Web of Science ®Google Scholar
• Szkandera J, Absenger G, Stotz M, et al. The functional polymorphism of erythropoietin gene rs1617640 G>T is not associated with susceptibility and clinical outcome of early-stage breast cancer. Anticancer Res. 2012;32(8):3473–3478.
   PubMed Web of Science ®Google Scholar
• Tzvetkov M, Behrens G, O’Brien V, et al. Pharmacogenetic analyses of cisplatin-induced nephrotoxicity indicate a renoprotective effect of ERCC1 polymorphisms. Pharmacogenomics. 2011;12(10):1417–1427. .
   PubMed Web of Science ®Google Scholar
• Tóvári J, Gilly R, Rásó E, et al. Recombinant human erythropoietin alpha targets intratumoral blood vessels, improving chemotherapy in human xenograft models. Cancer Res. 2005;65(16):7186–7193. .
   PubMed Web of Science ®Google Scholar
• Lövey J, Bereczky B, Gilly R, et al. Recombinant human erythropoietin alpha improves the efficacy of radiotherapy of a human tumor xenograft, affecting tumor cells and microvessels. Strahlentherapie und Onkologie. 2008;184(1):1–7.
   PubMed Web of Science ®Google Scholar
• Rózsás A, Berta J, Rojkó L, et al. Erythropoietin receptor expression is a potential prognostic factor in human lung adenocarcinoma. PloS One. 2013;8(10):e77459. .
   PubMed Web of Science ®Google Scholar
• Belozerov V, Van Meir E. Hypoxia inducible factor-1: a novel target for cancer therapy. Anticancer Drugs. 2005;16(9):901–909.
   PubMed Web of Science ®Google Scholar
• Doleschel D, Rix A, Arns S, et al. Erythropoietin improves the accumulation and therapeutic effects of carboplatin by enhancing tumor vascularization and perfusion. Theranostics. 2015;5(8):905–918. .
   PubMed Web of Science ®Google Scholar
• Wood P, Hrushesky W. Cisplatin-associated anemia: an erythropoietin deficiency syndrome. J Clin Invest. 1995;95(4):1650–1659.
   PubMed Web of Science ®Google Scholar
• Popov A, Schulz E, Schmitto J, et al. Relation between renal dysfunction requiring renal replacement therapy and promoter polymorphism of the erythropoietin gene in cardiac surgery. Artif Organs. 2010;34(11):961–968. .
   PubMed Web of Science ®Google Scholar
• Eshraghi-Jazi F, Nematbakhsh M, Pezeshki Z, et al. Sex differences in protective effect of recombinant human erythropoietin against cisplatin-induced nephrotoxicity in rats. Iran J Kidney Dis. 2013;7(5):383–389.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Rogers H, Zhang X, et al. Sex difference in mouse metabolic response to erythropoietin. Faseb J. 2017;31(6):2661–2673. .
   PubMed Web of Science ®Google Scholar
• Horiguchi H, Oguma E, Sakamoto T, et al. Suppression of erythropoietin induction by diethylstilbestrol in rats. Arch Toxicol. 2014;88(1):137–144. .
   PubMed Web of Science ®Google Scholar
• Pezeshki Z, Nematbakhsh M, Mazaheri S, et al. Estrogen abolishes protective effect of erythropoietin against cisplatin-induced nephrotoxicity in ovariectomized rats. ISRN Oncol. 2012;2012:890310.
   PubMedGoogle Scholar